Effects of exenatide on glycemic control over 52 weeks in patients with type 2 diabetes
- Author:
Xian SU
1
Author Information
- Publication Type:Journal Article
- Keywords: Exenatide; Insulin glargine; Type 2 diabetes mellitus
- From: Chinese Pharmaceutical Journal 2014;49(11):941-943
- CountryChina
- Language:Chinese
- Abstract: OBJECTIVE: To observe the effect and safety of exenatide therapy in type 2 diabetes patients with failure to metformin. METHODS: Sixty patients with type 2 diabetes who did not achieve satisfactory blood glucose control were randomly assigned either to add exenatide or glargine. postprandial blood glucose, HbA1C, blood lipid, and body mass index of the patients before and after treatment were recorded, and the side effects were also recorded for 52 weeks. RESULTS: The FPG and HbA1C of patients decreased more significantly after exenatide therapy than glargine treatment (P<0.05). The exenatide group had a significantly higher level of ΔHOMA-13 than the glargine group. CONCLUSION: Exenatide can be used for long-term control of blood glucose with improving lipid metabolism and low occurrence of hypoglycemia, without increasing body weight.
